testing the addition of the antibody, bevacizumab, to the usual treatment for radionecrosis that results from brain radiation

What we are studying

The purpose of this study is test whether adding a drug called bevacizumab to standard corticosteroid therapy will improve symptoms over corticosteroid therapy alone by improving the radionecrosis and minimizing treatment-related side effects

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • No clinically significant cardiovascular disease

What is involved

  • Study participants will be randomized to receive bevacizumab or placebo and standard corticosteroid therapy


Parking will be validated for all study related visits

Contact Information

Study Coordinator
Ashley Fansler, RN

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.